Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison

Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. Th...

Descripción completa

Detalles Bibliográficos
Autores: Pilotto, Andrea, Quaresima, Virginia, Trasciatti, Chiara, Tolassi, Chiara, Bertoli, Diego, Mordenti, Cristina, Galli, Alice, Rizzardi, Andrea, Caratozzolo, Salvatore, Zancanaro, Andrea, Contador, José, Hansson, Oskar, Palmqvist, Sebastian, De Santis, Giovanni, Zetterberg, Henrik, Blennow, Kaj, Brugnoni, Duilio, Suárez-Calvet, Marc, Ashton, Nicholas J., Padovani, Alessandro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:dnet:recercat____::a9d9b6ac94515b2278d685612944c428
Acceso en línea:https://hdl.handle.net/10230/72956
http://dx.doi.org/10.1093/brain/awae368
Access Level:acceso abierto
Palabra clave:ALZPath
Alzheimer&apos
s disease
Lumipulse
SIMOA
p-tau217
Plasma markers
id ES_a5ece28ceed8aeea46b7a236dfb238fe
oai_identifier_str oai:dnet:recercat____::a9d9b6ac94515b2278d685612944c428
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
title Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
spellingShingle Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
Pilotto, Andrea
ALZPath
Alzheimer&apos
s disease
Lumipulse
SIMOA
p-tau217
Plasma markers
title_short Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
title_full Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
title_fullStr Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
title_full_unstemmed Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
title_sort Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
dc.creator.none.fl_str_mv Pilotto, Andrea
Quaresima, Virginia
Trasciatti, Chiara
Tolassi, Chiara
Bertoli, Diego
Mordenti, Cristina
Galli, Alice
Rizzardi, Andrea
Caratozzolo, Salvatore
Zancanaro, Andrea
Contador, José
Hansson, Oskar
Palmqvist, Sebastian
De Santis, Giovanni
Zetterberg, Henrik
Blennow, Kaj
Brugnoni, Duilio
Suárez-Calvet, Marc
Ashton, Nicholas J.
Padovani, Alessandro
author Pilotto, Andrea
author_facet Pilotto, Andrea
Quaresima, Virginia
Trasciatti, Chiara
Tolassi, Chiara
Bertoli, Diego
Mordenti, Cristina
Galli, Alice
Rizzardi, Andrea
Caratozzolo, Salvatore
Zancanaro, Andrea
Contador, José
Hansson, Oskar
Palmqvist, Sebastian
De Santis, Giovanni
Zetterberg, Henrik
Blennow, Kaj
Brugnoni, Duilio
Suárez-Calvet, Marc
Ashton, Nicholas J.
Padovani, Alessandro
author_role author
author2 Quaresima, Virginia
Trasciatti, Chiara
Tolassi, Chiara
Bertoli, Diego
Mordenti, Cristina
Galli, Alice
Rizzardi, Andrea
Caratozzolo, Salvatore
Zancanaro, Andrea
Contador, José
Hansson, Oskar
Palmqvist, Sebastian
De Santis, Giovanni
Zetterberg, Henrik
Blennow, Kaj
Brugnoni, Duilio
Suárez-Calvet, Marc
Ashton, Nicholas J.
Padovani, Alessandro
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ALZPath
Alzheimer&apos
s disease
Lumipulse
SIMOA
p-tau217
Plasma markers
topic ALZPath
Alzheimer&apos
s disease
Lumipulse
SIMOA
p-tau217
Plasma markers
description Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. The study included 392 participants, 162 with Alzheimer's disease, 70 with other neurodegenerative diseases with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate Alzheimer's disease from other neurodegenerative diseases and controls was investigated using receiver operating characteristic analyses. The p-tau217 levels measured by the two techniques demonstrated a strong correlation, showing a consistent relationship with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating Alzheimer's disease from other neurodegenerative diseases [area under the curve (AUC) 0.952, 95% confidence interval (CI) 0.927-0.978 versus 0.955, 95% CI 0.928-0.982, respectively] and healthy controls (AUC 0.938, 95% CI 0.910-0.966 and 0.937, 95% CI 0.907-0.967 for both assays). This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer's disease using fully automated or semi-automated techniques.
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/10230/72956
http://dx.doi.org/10.1093/brain/awae368
https://hdl.handle.net/10230/72956
url https://hdl.handle.net/10230/72956
http://dx.doi.org/10.1093/brain/awae368
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Brain. 2025;148(2):408-15
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415655868989440
spelling Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparisonPilotto, AndreaQuaresima, VirginiaTrasciatti, ChiaraTolassi, ChiaraBertoli, DiegoMordenti, CristinaGalli, AliceRizzardi, AndreaCaratozzolo, SalvatoreZancanaro, AndreaContador, JoséHansson, OskarPalmqvist, SebastianDe Santis, GiovanniZetterberg, HenrikBlennow, KajBrugnoni, DuilioSuárez-Calvet, MarcAshton, Nicholas J.Padovani, AlessandroALZPathAlzheimer&aposs diseaseLumipulseSIMOAp-tau217Plasma markersPlasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. The study included 392 participants, 162 with Alzheimer's disease, 70 with other neurodegenerative diseases with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate Alzheimer's disease from other neurodegenerative diseases and controls was investigated using receiver operating characteristic analyses. The p-tau217 levels measured by the two techniques demonstrated a strong correlation, showing a consistent relationship with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating Alzheimer's disease from other neurodegenerative diseases [area under the curve (AUC) 0.952, 95% confidence interval (CI) 0.927-0.978 versus 0.955, 95% CI 0.928-0.982, respectively] and healthy controls (AUC 0.938, 95% CI 0.910-0.966 and 0.937, 95% CI 0.907-0.967 for both assays). This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer's disease using fully automated or semi-automated techniques.The research is supported by an Associazione Italiana Ricerca Alzheimer AGYR2021 Life-Bio Grant, Ministero dell’Istruzione, dell’Università e della Ricerca, Italy, PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (2020PNRR2THZAW), Ministero della Salute, Italy, Grant/Award Number: RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. A.Pi. has been supported by grants from the Associazione Italiana Ricerca Alzheimer AGYR2021 Life-Bio Grant, the LIMPE-DISMOV Foundation Segala Grant 2021, Ministero dell’Istruzione, dell’Università e della Ricerca PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 European Research Council IMI IDEA-FAST (ID853981), Ministero della Salute Grant/Award Number: RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. is supported by the H2020 IMI IDEA-FAST (ID853981). C.Tra. is supported by Ministero dell’Istruzione, dell’Università e della Ricerca. C.To. is supported by the Ministero della Salute PRIN 2021 RePlast. A.G. is supported by the Ministero della Salute PRIN 2021 RePlast and the H2020 European Research Council IMI IDEA-FAST (ID853981). A.R. is supported by the H2020 European Research Council IMI IDEA-FAST (ID853981) and the PNRR-Health PNRR-MAD-2022-12376110. O.H. was supported by the European Research Council (ADG-101096455), Alzheimer’s Association (ZEN24-1069572, SG-23-1061717), the GHR Foundation, Vetenskapsrådet (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut och Alice Wallenberg Stiftelse (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, Alzheimerfonden (AF-980907), Hjärnfonden (FO2021-0293), Parkinsonfonden (1412/22), the Cure Alzheimer’s Fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Region Skåne Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080). S.P. is supported by the National Institute on Aging (USA; #R01AG083740), the Swedish Research Council (#2018-02052), Alzheimerfonden (#AF-994075), Hjärnfonden (#FO2022-0204), and the Family Rönström’s Foundation (#FRS-0004). H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council, supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research UCLH Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017-00915 and 2022-00732), Alzheimerfonden, Sweden (AF-930351, AF-939721, and AF-968270), Hjärnfonden, Sweden (FO2017-0243 and ALZ2022-0006), Swedish state under the agreement between the Swedish government and the County Councils, ALF-agreement (ALFGBG-715986 and ALFGBG-965240), European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and Alzheimer’s Association 2022-2025 grant (SG-23-1038904 QC). The Wisconsin Registry for Alzheimer’s Prevention is supported by National Institutes of Health grants AG027161 and AG021155. M.S.C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project ‘PI19/00155’ and ‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement No 847648 (LCF/BQ/PR21/11840004). A.Pa. has been supported by grants of the Ministero dell’Istruzione, dell’Università e della Ricerca PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981), Italian Ministry of Health, Grant/Award Number: RF-2018-12366209, RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110.Oxford University Press2026202620252026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/10230/72956http://dx.doi.org/10.1093/brain/awae368https://hdl.handle.net/10230/72956reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésBrain. 2025;148(2):408-15© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:dnet:recercat____::a9d9b6ac94515b2278d685612944c4282026-05-29T05:05:01Z
score 15,81155

Similares en LA Referencia